American Century Companies
ZVRA icon

American Century Companies’s Zevra Therapeutics ZVRA Stock Holding History

American Century Companies’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,159
Closed -$105K – 2961
2024
Q1 		$105K Sell
18,159
-524
-3% -$3.22K ﹤0.01% 2857
2023
Q4 		$122K Buy
18,683
+1,004
+6% +$4.7K ﹤0.01% 2789
2023
Q3 		$85.2K Buy
17,679
+4,199
+31% +$21K ﹤0.01% 2745
2023
Q2 		$68.7K Buy
+13,480
New +$72.6K ﹤0.01% 2736

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

American Century Companies's ZVRA Position: Q2 2024 in Review

American Century Companies sold out of Zevra Therapeutics (ZVRA) in Q2 2024, closing a stake of 18,159 shares — an estimated $105K sold.

American Century Companies first reported a position in ZVRA in Q2 2023 and held it in 4 quarters. The position peaked at $122K in Q4 2023. 93 funds tracked by Wall St. Rank hold ZVRA as of Q2 2024.

  • American Century Companies reported no remaining Zevra Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American Century Companies sold 18,159 Zevra Therapeutics shares in Q2 2024, an estimated $105K.
  • American Century Companies first reported a position in Zevra Therapeutics in Q2 2023 and held it in 4 quarters.
  • American Century Companies's Zevra Therapeutics position peaked at $122K in Q4 2023.
  • 93 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2024.

Based on American Century Companies's 13F filing for Q2 2024, filed 7 Aug 2024.